The 126 Devices Exempted from Registration: List and Scope

1. Key takeaways

Myanmar maintains a list of exempted devices, and devices on that list are exempted from obtaining the corresponding certificates. The list was announced and expanded at the 7th ASEAN Medical Device Committee (AMDC) meeting, and public sources consistently record it as 126 devices.

GRZAN note: the exemption determination must follow a three-step method — (1) confirm whether the product falls within the exemption list → (2) confirm the precise scope of the exemption (product / model / intended use) → (3) obtain written confirmation from the Myanmar FDA that the exemption applies. Claiming an exemption based merely on a similar product name is a frequent cause of customs clearance blockages. The three-step method exists precisely because the boundary between exempted and non-exempted devices is drawn at the level of the specific device entry, and because the consequences of crossing that boundary wrongly are felt at the port rather than at the desk.

In practical terms, the exemption list changes the entry economics for a small number of low-risk items, but it does not change the compliance architecture that surrounds them. The same quality, labelling and post-market expectations continue to apply, and the documentation trail supporting the exemption determination becomes part of the company’s regulatory record. For that reason, the effort saved on certificates should be redirected to the determination work itself, which is where the real risk sits.

2. Legal basis

3. Expert insights

Insight 1: in legal terms the exemption list is a certificate exemption, not a regulatory exemption. What falling within the list removes is the obligation to obtain certificates such as the Import Recommendation or Import Notification; it does not remove quality requirements, labelling requirements or post-market obligations. This distinction is frequently confused in practice, particularly by distributors who assume that absence from the registration requirement implies absence from any regulatory duty at all.

Insight 2: the exemption determination must be precise to the model and intended use, not merely to the product category. The official wording emphasises “126 devices”, meaning the unit of determination is the individual device entry. Companies must check whether the specific description of their own product matches the entry on the list, field by field, including the device name, the model designation and the stated intended purpose. Where any of these fields diverges, the safest reading is that the exemption does not apply until the FDA says otherwise.

Insight 3: the list has been expanded before, which shows it is dynamically adjusted. The Myanmar FDA “expanded their exemption list” at the 7th AMDC meeting. Companies cannot rely on conclusions drawn from historical versions of the list; the current version is the only valid reference. A device exempted in an earlier list iteration may have been removed, and a device once subject to certification may have been added, so the determination must be refreshed at every new project and at every renewal.

Insight 4: the cost of an incorrect exemption determination concentrates at customs clearance. If an exemption is misjudged and no certificate is obtained, the goods cannot pass the document checks of customs and the FDA on arrival, and the cost of correction far exceeds the cost of registration itself. Beyond the direct financial loss, delayed deliveries damage customer relationships in ways that no compliance budget can repair after the fact.

Supplement to insight 4: alongside pre-market control, the system also comprises post-market surveillance and cross-authority coordination, and both of these steps apply equally to products that fall within the exemption list.

Insight 5: the third step of the three-step method (written confirmation) is the one most often skipped. Its internal value lies in creating traceable evidence of the position taken; in any later dispute or audit, the written answer can be cited directly as the basis of the company’s judgement. It also disciplines the internal decision process, because preparing a reasoned enquiry forces the team to state exactly which entry it relies on and why.

4. Practical recommendations

• Check the current version of the exemption list at the project initiation stage. Determine whether the product falls within the exemption scope before committing registration investment.
• Reconcile down to the model and intended use level. Do not judge broadly by product category.
• Obtain written FDA confirmation for borderline cases. Submit the enquiry through the local authorised representative and retain the reply.
• Apply quality and labelling requirements even when exempted. What is exempted is the certificate, not the obligation.
• Establish a version-tracking mechanism for the list. Because the list has been expanded before, judgements must always be made against the current version.

5. Verification checklist

• □ The current version of the exempted devices list has been obtained
• □ Item-by-item reconciliation at model and intended use level has been completed
• □ Written FDA confirmation has been obtained for borderline cases
• □ It has been confirmed that the exemption is a certificate exemption and not an obligation exemption
• □ A version-tracking mechanism for the list has been established
• □ The basis of the exemption determination has been recorded in internal documentation
• □ It has been confirmed that post-market obligations are not waived by the exemption

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Myanmar. Our team prepares the technical dossier to ASEAN CSDT structure, manages submission and deficiency responses with the Myanmar FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com